Literature DB >> 15625026

Assessment and management of disability in chronic daily headache.

William Pryse-Phillips1.   

Abstract

The problem of chronic daily headache is ubiquitous and affects up to 5% of the world's population. In most cases, it is associated with the overuse of symptomatic medications in patients with a history of migraine or tension-type headaches, indicating an urgent need for intensive public and professional education. In a minority, it develops de novo from episodic migraine without excessive drug intake. The condition is likely to have a biologic (rather than psychologic) basis. The degree with which it negatively impacts patients and their family is reviewed. Current treatment regimes are described, but it is noted that those currently employed are seldom adequate in the long term, possibly because of the unavailability of nonpharmacologic treatments to most people or because of the low frequency of use of preventative pharmacologic and lifestyle measures.

Entities:  

Mesh:

Year:  2005        PMID: 15625026     DOI: 10.1007/s11916-005-0075-7

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  49 in total

1.  Quality-of-life differences between patients with episodic and transformed migraine.

Authors:  D M Meletiche; J H Lofland; W B Young
Journal:  Headache       Date:  2001-06       Impact factor: 5.887

2.  Chronic daily headache: identification of factors associated with induction and transformation.

Authors:  Marcelo E Bigal; Fred D Sheftell; Alan M Rapoport; Stewart J Tepper; Richard B Lipton
Journal:  Headache       Date:  2002 Jul-Aug       Impact factor: 5.887

3.  Chronic daily headache in Taipei, Taiwan: prevalence, follow-up and outcome predictors.

Authors:  S R Lu; J L Fuh; W T Chen; K D Juang; S J Wang
Journal:  Cephalalgia       Date:  2001-12       Impact factor: 6.292

4.  Long-term follow-up of patients treated for chronic headache with analgesic overuse.

Authors:  L A Pini; A F Cicero; M Sandrini
Journal:  Cephalalgia       Date:  2001-11       Impact factor: 6.292

Review 5.  Chronic daily headache and the revised international headache society classification.

Authors:  Morris Levin
Journal:  Curr Pain Headache Rep       Date:  2004-02

Review 6.  Medication-overuse headache: a worldwide problem.

Authors:  Hans-Christoph Diener; Volker Limmroth
Journal:  Lancet Neurol       Date:  2004-08       Impact factor: 44.182

7.  Headache management program improves outcome for chronic headache.

Authors:  Linda H Harpole; Gregory P Samsa; Annette E Jurgelski; Janice L Shipley; Allan Bernstein; David B Matchar
Journal:  Headache       Date:  2003 Jul-Aug       Impact factor: 5.887

8.  Self-reported headache frequency and features associated with frequent headaches in Canadian young adolescents.

Authors:  K E Gordon; J M Dooley; E P Wood
Journal:  Headache       Date:  2004-06       Impact factor: 5.887

9.  Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine.

Authors:  Marcelo E Bigal; Alan M Rapoport; Richard B Lipton; Stewart J Tepper; Fred D Sheftell
Journal:  Headache       Date:  2003-04       Impact factor: 5.887

10.  Intravenous lignocaine (lidocaine) infusion for the treatment of chronic daily headache with substantial medication overuse.

Authors:  D R Williams; R J Stark
Journal:  Cephalalgia       Date:  2003-12       Impact factor: 6.292

View more
  2 in total

1.  Botulinum toxin A for prophylaxis of chronic daily headaches.

Authors:  Jerry W Swanson
Journal:  Curr Neurol Neurosci Rep       Date:  2007-03       Impact factor: 5.081

2.  Low omega-6 vs. low omega-6 plus high omega-3 dietary intervention for chronic daily headache: protocol for a randomized clinical trial.

Authors:  Christopher E Ramsden; J Douglas Mann; Keturah R Faurot; Chanee Lynch; Syed Taha Imam; Beth A MacIntosh; Joseph R Hibbeln; James Loewke; Sunyata Smith; Rebecca Coble; Chirayath Suchindran; Susan A Gaylord
Journal:  Trials       Date:  2011-04-15       Impact factor: 2.279

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.